MabThera shows improved leukaemia survival benefits Pharmafocus MabThera/Rituxan is the first treatment to show improved survival in previously untreated patients with chronic lymphocytic leukaemia (CLL), according to Roche. Updated study results were presented at the 51st Meeting of the American Society of … Australia's premier lab supplies news website Medical Devices+Equipment CCL8 Data Coming to ASH Gerson Lehrman Group Genentech and Biogen Idec Present Follow Up Trial Results at ASH Annual Meeting Trading Markets (press release) Canada NewsWire (press release) ?- News-Medical.net all 9 news articles??

More: 
MabThera shows improved leukaemia survival benefits – Pharmafocus